Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;116(2):355-358.
doi: 10.36660/abc.20210031.

Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF

[Article in English, Portuguese]
Edimar Alcides Bocchi  1 , Andréa Biolo  2   3   4 , Lidia Zytynski Moura  5 , José Albuquerque Figueiredo Neto  6 , Carlos Eduardo Lucena Montenegro  7 , Denilson Campos de Albuquerque  8   9
Affiliations

Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF

[Article in English, Portuguese]
Edimar Alcides Bocchi et al. Arq Bras Cardiol. 2021 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potencial conflito de interesses

Dr. Edimar Bocchi - Honorário de consultoria/palestra: Boehringer Ingelheim, Astra Zeneca. Verba de pesquisa: Astra Zeneca. Projetos de pesquisa: Boehringer Ingelheim, Astra Zeneca.

Dra. Lidia Zytynski Moura – Palestrante e do conselho consultivo da empresa Astra Zeneca.

Dr. Carlos Eduardo Lucena Montenegro – Palestrante da Astra Zeneca.

Dr. José Albuquerque de Figueiredo Neto - Palestrante da Astra Zeneca.

Dr. Denilson Campos de Albuquerque – Pesquisador estudo Emperor. Conselho consultivo e palestra para Boehringer Ingelheim e Astra Zeneca.

Figures

Figura 1
Figura 1. – Mecanismos de ação do iSGLT2. ISGLT2: inibidores do cotransportador de sódio-glicose-2.
Figura 2
Figura 2. Redução de hospitalização por insuficiência cardíaca nos estudos com ISGLT2. ISGLT2: inibidores do cotransportador de sódio-glicose-2; RRR: Redução do Risco Relativo; HR: hazard ratio; IC: intervalo de confiança.
Figure 1
Figure 1. – SGLT2i: mechanisms of action.
Figure 2
Figure 2. – Reduction in hospitalization for heart failure in SGLT2i studies. RRR: relative risk reduction.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. . Verna, S., McMurray, J.J.V. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 2018. - PubMed
    2. Verna S, McMurray J.J.V. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018 - PubMed
    1. . Lopaschuk, GD and Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci, 2020; 5(6):632-644. - PMC - PubMed
    2. Lopaschuk GD and Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020;5(6):632–644. - PMC - PubMed
    1. . Fitchett D, Inzucchi SE, Cannon CP et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation, 2019; 139(11): 1384–1395. - PMC - PubMed
    2. Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019;139(11):1384–1395. - PMC - PubMed
    1. . Wanner C, Lachin JM, Inzucchi SE et al (2018) Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137:119–129. - PubMed
    2. Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119–129. - PubMed
    1. . Verma S, McMurray JJV, Cherney DZI (2017) The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2:939–940. - PubMed
    2. Verma S, McMurray JJV, Cherney DZI. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol. 2017;2:939–940. - PubMed